Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery

다국어 초록 (Multilingual Abstract)

Solid lipid-based nanoparticles (SLBNs) were developed as potential alternatives to other conventional drug delivery systems such as polymeric nanoparticles, liposomes,and emulsions. In general, SLBNs are divided into two types: solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). SLNs are distinguishable from NLCs by the composition of solid particle matrix. SLBNs can be prepared by several methods including high pressure homogenization, solvent emulsification (or diffusion)-evaporation, and microemulsion technologies. Then, SLBNs can be characterized in terms of particle size distribution,surface charge, morphology, and crystallinity. SLBNs are well-tolerated and efficient carrier systems for parenteral,oral, inhalational, ocular, and dermal applications. This review provides an overview of the preparation and characterization technologies for SLBNs and focuses on recent advances in drug delivery using SLBNs.

참고문헌 (Reference)

1 Bargoni A, "Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II–tissue distribution" 43 : 497-502, 2001

2 Kim JE, "The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin" TAYLOR & FRANCIS LTD 43 : 579-591, 2013

3 Yang R, "The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process" 37 : 139-148, 2011

4 Attama AA, "Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea" 34 : 698-705, 2009

5 Holm R, "Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats" 19 : 1354-1361, 2002

6 Radomska-Soukharev A, "Stability of lipid excipients in solid lipid nanoparticles" 59 : 411-418, 2007

7 Schubert MA, "Solvent injection as a new approach for manufacturing lipid nanoparticles––evaluation of the method and process parameters" 55 : 125-131, 2003

8 Pandey R, "Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis" 85 : 227-234, 2005

9 Mehnert W, "Solid lipid nanoparticles: production, characterization and applications" 47 : 165-196, 2001

10 Harde H, "Solid lipid nanoparticles: an oral bioavailability enhancer vehicle" 8 : 1407-1424, 2011

11 Liu J, "Solid lipid nanoparticles for pulmonary delivery of insulin" 356 : 333-344, 2008

12 Maia CS, "Solid lipid nanoparticles as drug carriers for topical glucocorticoids" 196 : 165-167, 2000

13 Shidhaye SS, "Solid lipid nanoparticles and nanostructured lipid carriers–– innovative generations of solid lipid carriers" 5 : 324-331, 2008

14 Muller RH, "Solid lipid nanoparticles (SLN) for controlled drug delivery..a review of the state of the art" 50 : 161-177, 2000

15 Cavalli R, "Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin" 238 : 241-245, 2002

16 Muller RH, "Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations" 54 (54): S131-S155, 2002

17 Bunjes H, "Saturated phospholipids promote crystallization but slow down polymorphic transitions in triglyceride nanoparticles" 107 : 229-243, 2005

18 윤인수, "Saturable sinusoidal uptake is rate-determining process in hepatic elimination of docetaxel in rats" INFORMA HEALTHCARE 42 (42): 1110-1119, 2012

19 Kuchler S, "SLN for topical application in skin diseases..characterization of drug-carrier and carrier-target interactions" 390 : 225-233, 2010

20 Zhang XG, "Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells" 361 : 239-244, 2008

21 Das S, "Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery" 12 : 62-76, 2011

22 Obeidat WM, "Preservation of nanostructured lipid carriers (NLC)" 76 : 56-67, 2010

23 Mukherjee B, "Preparation, characterization and in vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers" 3 : 487-496, 2008

24 Hu FQ, "Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization" 239 : 121-128, 2002

25 Charcosset C, "Preparation of solid lipid nanoparticles using a membrane contactor" 108 : 112-120, 2005

26 Trotta M, "Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique" 257 : 153-160, 2003

27 Zhuang CY, "Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability" 394 : 179-185, 2010

28 Hu FQ, "Preparation and characteristics of monostearin nanostructured lipid carriers" 314 : 83-89, 2006

29 Souto EB, "Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC" 23 : 417-433, 2006

30 Zimmermann E, "Physicochemical investigations on the structure of drug-free and drug-loaded solid lipid nanoparticles (SLN) by means of DSC and 1H NMR" 60 : 508-513, 2005

31 Chan J, "Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation" 328 : 65-71, 2007

32 Gill PS, "Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin" 13 : 996-1003, 1995

33 Manjunath K, "Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration" 107 : 215-228, 2005

34 Yoon IS, "Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol" 41 : 243-251, 2011

35 Han SY, "Pharmacokinetic interaction between metoprolol and SP-8203 in rats: competitive inhibition for themetabolism ofmetoprolol by SP- 8203 via hepatic CYP2D subfamily" 42 : 1017-1027, 2012

36 Shahgaldian P, "Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters" 253 : 23-38, 2003

37 Koziara JM, "Paclitaxel nanoparticles for the potential treatment of brain tumors" 99 : 259-269, 2004

38 Gavini E, "PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies" 57 : 207-212, 2004

39 Muller RH, "Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals" 317 : 82-89, 2006

40 Tsai MJ, "Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations" 100 : 547-557, 2011

41 Griffin BT, "Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies" 2 : 1633-1653, 2011

42 Muller RH, "Nanostructured lipid matrices for improved microencapsulation of drugs" 242 : 121-128, 2002

43 Iqbal MA, "Nanostructured lipid carriers system: recent advances in drug delivery" 20 : 813-830, 2012

44 Liu D, "Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel" 85 : 262-269, 2011

45 Muller RH, "Nanostructured lipid carriers (NLC) in cosmetic dermal products" 59 : 522-530, 2007

46 Joshi M, "Nanostructured lipid carrier (NLC) based gel of celecoxib" 346 : 124-132, 2008

47 Jaques PA, "Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women" 12 : 715-731, 2000

48 Qing-yu Xiang, "Lung-Targeting Delivery of Dexamethasone Acetate Loaded Solid Lipid Nanoparticles" 대한약학회 30 (30): 519-525, 2007

49 Li N, "Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery" 379 : 131-138, 2009

50 Charman WN, "Lipids, lipophilic drugs, and oral drug delivery––some emerging concepts" 89 : 967-978, 2000

51 Puri A, "Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic" 26 : 523-580, 2009

52 Battaglia L, "Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery" 9 : 497-508, 2012

53 Schafer-Korting M, "Lipid nanoparticles for improved topical application of drugs for skin diseases" 59 : 427-443, 2007

54 Pardeike J, "Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products" 366 : 170-184, 2009

55 Estella-Hermoso de Mendoza A, "Lipid nanomedicines for anticancer drug therapy" 5 : 323-343, 2009

56 Aungst BJ, "Intestinal permeation enhancers" 89 : 429-442, 2000

57 Braem C, "Interaction of drug molecules with carrier systems as studied by parelectric spectroscopy and electron spin resonance" 119 : 128-135, 2007

58 Ye J, "Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis" 352 : 273-279, 2008

59 Harivardhan Reddy L, "Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton’s lymphoma tumor bearing mice" 105 : 185-198, 2005

60 Hu L, "Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles" 65 : 110-113, 2010

61 Uner M, "Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives" 2 : 289-300, 2007

62 Patlolla RR, "Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers" 144 : 233-241, 2010

63 Xie S, "Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles" 5 : 693-701, 2010

64 Doijad RC, "Formulation and targeting efficiency of Cisplatin engineered solid lipid nanoparticles" 70 : 203-207, 2008

65 Varshosaz J, "Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability" 20 : 286-296, 2010

66 Kakkar V, "Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin" 55 : 495-503, 2011

67 Zhang J, "Experimental design for the optimization of lipid nanoparticles" 98 : 1813-1819, 2009

68 Varshosaz J, "Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles" 20 : 115-123, 2010

69 Li H, "Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles" 133 : 238-244, 2009

70 Chen CC, "Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics" 74 : 474-482, 2010

71 Sanjula B, "Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement" 17 : 249-256, 2009

72 Paliwal R, "Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery" 5 : 184-191, 2009

73 Mosallaei N, "Docetaxel-loaded solid lipid nanoparticles: preparation, characterization, in vitro, and in vivo evaluations" 102 : 1994-2004, 2013

74 Sahana B, "Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in vitro evaluation" 5 : 621-630, 2010

75 Pardeike J, "Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application" 419 : 329-338, 2011

76 Cirri M, "Development of a new delivery system consisting in ‘‘drug–in cyclodextrin–in nanostructured lipid carriers’’ for ketoprofen topical delivery" 80 : 46-53, 2012

77 Anton N, "Design and production of nanoparticles formulated from nano-emulsion templates––a review" 128 : 185-199, 2008

78 Gonzalez-Mira E, "Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC" 81 : 412-421, 2010

79 Stecova J, "Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake" 24 : 991-1000, 2007

80 Muller RH, "Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation" 68 : 535-544, 2008

81 Gokce EH, "Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes" 34 : 996-1003, 2009

82 Lin YK, "Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery" 5 : 117-128, 2010

83 Teeranachaideekul V, "Cetyl palmitate-based NLC for topical delivery of coenzyme Q(10)––development, physicochemical characterization and in vitro release studies" 67 : 141-148, 2007

84 Garcia-Fuentes M, "Application of NMR spectroscopy to the characterization of PEG-stabilized lipid nanoparticles" 20 : 8839-8845, 2004

85 Pandey R, "Antitubercular inhaled therapy: opportunities, progress and challenges" 55 : 430-435, 2005

86 Lauweryns JM, "Alveolar clearance and the role of the pulmonary lymphatics" 115 : 625-683, 1977

87 Patel M, "Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles" 10 : 889-905, 2013

88 Muller RH, "20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications" 8 : 207-227, 2011